Robert Foerster1, Lars Schroeder2, Frank Foerster3, Volker Wulff4, Birgit Schubotz5, Dieter Baaske6, Christian Rudlowski2. 1. Department of Radiation Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany. 2. Department of Gynecology and Obstetrics, University Hospital, Center of Integrated Oncology (CIO) Bonn, Germany. 3. Department of Economic Sciences, University of Applied Sciences, Zwickau, Germany ; Outpatient Department of Gynecologic Oncology, Poliklinik GmbH, Chemnitz, Germany. 4. Cancer Register of Southwest Saxony, Zwickau, Germany. 5. Cancer Register of Chemnitz, Chemnitz, Germany. 6. Cancer Register of Chemnitz, Chemnitz, Germany ; Department of Radiation Oncology, Klinikum Chemnitz, Chemnitz, Germany.
Abstract
BACKGROUND: Metastasized male breast cancer (MMBC) is a rare disease. Given its low incidence, data regarding tumor biology, current treatment options, and survival rates are scarce. PATIENTS AND METHODS: A chart review was performed of MMBC patients consecutively registered in regional cancer registries in Germany between 1995 and 2011. Tumor characteristics, treatment, and survival rates were documented and statistically evaluated. RESULTS: 41 men with MMBC represented 25.6% of a total of 160 patients with MBC. 16 (39%) patients showed primary metastases, and 25 (61%) had recurrent metastases. Median survival from occurrence of metastasis was 32 months. Median overall survival (OS) was 68 months. 68.3% (n = 28) of the cohort received systemic therapy favoring endocrine therapy (n = 25, 61.9%). Prolonged metastatic OS (p = 0.02) was observed in patients having had a systemic treatment. Metastatic patients having received endocrine treatment showed significantly prolonged survival rates. Furthermore, patients receiving palliative chemotherapy had a significant survival benefit compared to those in whom chemotherapy was omitted. CONCLUSION: Our results suggest that systemic treatment in the form of both palliative chemotherapy and endocrine therapy improves outcome of R. Foerster and L. Schroeder contributed equally to this article and are listed in alphabetical order. MMBC. Therefore, it seems reasonable that treatment of MMBC should be based on the guidelines for female breast cancer.
BACKGROUND:Metastasized male breast cancer (MMBC) is a rare disease. Given its low incidence, data regarding tumor biology, current treatment options, and survival rates are scarce. PATIENTS AND METHODS: A chart review was performed of MMBCpatients consecutively registered in regional cancer registries in Germany between 1995 and 2011. Tumor characteristics, treatment, and survival rates were documented and statistically evaluated. RESULTS: 41 men with MMBC represented 25.6% of a total of 160 patients with MBC. 16 (39%) patients showed primary metastases, and 25 (61%) had recurrent metastases. Median survival from occurrence of metastasis was 32 months. Median overall survival (OS) was 68 months. 68.3% (n = 28) of the cohort received systemic therapy favoring endocrine therapy (n = 25, 61.9%). Prolonged metastatic OS (p = 0.02) was observed in patients having had a systemic treatment. Metastatic patients having received endocrine treatment showed significantly prolonged survival rates. Furthermore, patients receiving palliative chemotherapy had a significant survival benefit compared to those in whom chemotherapy was omitted. CONCLUSION: Our results suggest that systemic treatment in the form of both palliative chemotherapy and endocrine therapy improves outcome of R. Foerster and L. Schroeder contributed equally to this article and are listed in alphabetical order. MMBC. Therefore, it seems reasonable that treatment of MMBC should be based on the guidelines for female breast cancer.
Entities:
Keywords:
Male breast cancer; Metastasis; Prognosis
Authors: Larissa A Korde; Jo Anne Zujewski; Leah Kamin; Sharon Giordano; Susan Domchek; William F Anderson; John M S Bartlett; Karen Gelmon; Zeina Nahleh; Jonas Bergh; Bruno Cutuli; Giancarlo Pruneri; Worta McCaskill-Stevens; Julie Gralow; Gabriel Hortobagyi; Fatima Cardoso Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Holm Eggemann; Atanas Ignatov; Bobbie J Smith; Udo Altmann; Gunter von Minckwitz; Freidrich W Röhl; Mark Jahn; Serban-Dan Costa Journal: Breast Cancer Res Treat Date: 2012-12-09 Impact factor: 4.872
Authors: Mariana Chavez-Macgregor; Christina A Clarke; Daphne Lichtensztajn; Gabriel N Hortobagyi; Sharon H Giordano Journal: Cancer Date: 2013-01-22 Impact factor: 6.860
Authors: Roberto Gennari; Giuseppe Curigliano; Barbara A Jereczek-Fossa; Stefano Zurrida; Giuseppe Renne; Mattia Intra; Viviana Galimberti; Alberto Luini; Roberto Orecchia; Giuseppe Viale; Aron Goldhrisch; Umberto Veronesi Journal: Int J Oncol Date: 2004-03 Impact factor: 5.650
Authors: Sharon H Giordano; Aman U Buzdar; Terry L Smith; Shu-Wan Kau; Ying Yang; Gabriel N Hortobagyi Journal: Cancer Date: 2004-01-01 Impact factor: 6.860
Authors: Luigi Di Lauro; Laura Pizzuti; Maddalena Barba; Domenico Sergi; Isabella Sperduti; Marcella Mottolese; Pietro Del Medico; Franca Belli; Patrizia Vici; Ruggero De Maria; Marcello Maugeri-Saccà Journal: J Exp Clin Cancer Res Date: 2015-03-21